RESEARCH ARTICLE

Increased uptake of early initiation of antiretroviral therapy and baseline drug resistance testing in San Francisco between 2001 and 2015

Hong-Ha M. Truong¹,²*, Sharon Pipkin³, Robert M. Grant¹,², Teri Liegler¹, Kara J. O’Keefe³, Susan Scheer³

¹ Department of Medicine, University of California, San Francisco, United States of America, ² Gladstone Institute of Virology and Immunology, San Francisco, United States of America, ³ Department of Public Health, San Francisco, United States of America

* Hong-Ha.Truong@ucsf.edu

Abstract

Background

Early initiation of antiretroviral therapy (eiART) can improve clinical outcomes for persons with HIV and reduce onward transmission risk. Baseline drug resistance testing (bDRT) can inform regimen selection upon subsequent treatment initiation. We examined the uptake of eiART and bDRT within 3 months and 30 days of HIV diagnosis.

Methods

We analyzed a population-based sample from the San Francisco Department of Public Health HIV/AIDS Case Registry of newly-diagnosed HIV/non-AIDS individuals between 2001 and 2015 who received care at publicly-funded facilities (N = 3,124).

Results

Uptake of eiART within 3 months of diagnosis increased significantly from 2001 to 2015 (p < 0.001), peaking at 74% in 2015. bDRT uptake also increased significantly (p < 0.001), peaking at 55% in 2012. eiART uptake was observed to be significantly associated with gender, age, race/ethnicity and transmission risk. There were no significant differences observed in demographic and risk characteristics of persons receiving bDRT in the more recent years. Of 990 persons diagnosed between 2010 and 2015, eiART uptake within 30 days of diagnosis increased from 13% to 38% (p < 0.001); bDRT uptake increased from 35% to 39% but the change was not significant (p = 0.141).

Conclusions

Observed increases in eiART and bDRT uptake from 2010 to 2015 may reflect the adoption of treatment as prevention and a local public health policy statement in 2010 recommending treatment initiation at time of diagnosis irrespective of CD4 count. Concerns about stigma...
Introduction

HIV treatment guidelines in the US have evolved greatly over the past decade. Historically, antiretroviral therapy (ART) initiation was based on CD4 T cell counts. Prior to 2007, ART initiation was recommended when CD4+ lymphocyte count (CD4 count) dropped below 200 cells/mm$^3$. Treatment guidelines revisions were revised to recommend ART initiation at CD4 $<350$ in 2007 and CD4 $<500$ in 2009.[1]

Informed by clinical trials demonstrating starting ART early improves clinical outcomes for persons with HIV and reduces onward transmission risk, national treatment guidelines have recommended early initiation of ART (eiART) irrespective of CD4 count since 2012.[1–3] Prior to the national guideline revisions, the San Francisco Department of Public Health issued a policy statement in 2010 recommending ART initiation at time of diagnosis.[4]

Additionally, HIV-1 drug resistance testing (DRT) has long been recommended for the clinical management of patients failing treatment. When a regimen change is indicated due to virologic failure, DRT can guide the selection of drugs effective against the HIV strains a patient carries. Improvements in short-term virologic response to treatment when DRT results are available to clinician have been documented.[5]

DRT during early stages of infection has additional benefits. Baseline DRT (bDRT) upon diagnosis and prior to ART initiation can detect transmitted drug resistance mutants present early in the course of infection that decrease over time but might still persist at undetectable levels in the absence of ART.[6,7] bDRT was proposed as “reasonable to consider” in 2003 and first officially recommended in 2007.[1]

The present analysis examined the uptake of eiART and bDRT within both 3 months and 30 days of HIV diagnosis. We also assessed demographic, risk and clinical characteristics of newly-diagnosed persons with eiART and bDRT uptake.

Methods

We analyzed a population-based sample of San Francisco residents newly-diagnosed with HIV/non-AIDS from 2001 through 2015 who received care at publicly-funded facilities. HIV/non-AIDS was defined as CD4 count $\geq 200$ cells/mm$^3$ and the absence of an AIDS-indicator condition at time of diagnosis. Receipt of care was defined as having either a CD4 count or an HIV viral load laboratory result. Data were obtained from the San Francisco Department of Public Health HIV/AIDS Case Registry, and the AIDS Research Institute (ARI) University of California, San Francisco (UCSF) Laboratory of Clinical Virology (LCV) which performs drug resistance testing for all local publicly-funded clinics.

Persons not ART-naïve at time of diagnosis were excluded from all analyses. ART initiation date was determined based on the prescription date indicated in the medical records. DRT date was based on the specimen collection date. Two definitions of eiART were used: 1) initiating ART within 3 months of diagnosis; and 2) initiating ART within 30 days of diagnosis. Two definitions of bDRT were used: 1) DRT within 3 months of diagnosis and prior to ART initiation; and 2) DRT within 30 days of diagnosis and prior to ART initiation. The timeframe (3 months or 30 days) was specified in each analysis. Since recommendations for eiART upon
diagnosis began in San Francisco in 2010 and nationally in 2012, we assessed eiART and bDRT within 30 days of diagnosis for persons diagnosed between 2010 and 2015.

Demographic and risk characteristics included gender, age, race/ethnicity and HIV transmission risk category. Clinical characteristics included HIV diagnosis date, first DRT date and ART initiation date. Cases were characterized by diagnosis year and stratified by treatment guideline eras. Diagnosis years were grouped into eras based on treatment guidelines or when a significant local policy on ART was implemented. Era 1 spanned from 2001 through 2003, Era 2 from 2004 through 2006, Era 3 from 2007 through 2009, Era 4 from 2010 through 2012, and Era 5 from 2013 through 2015.

eiART and bDRT temporal trends and associations with demographic, risk and clinical characteristics were assessed by Chi-Square and Fisher’s Exact tests, and multivariable logistic regression. The study received approval from the UCSF Institutional Review Board. A waiver of informed consent was granted with the stipulation that all identifiable patient data, e.g., clinical results, and demographic and risk characteristics, would be maintained securely behind the mandatory data firewall of the San Francisco Department of Public Health.

Results

A total of 3,124 persons newly-diagnosed with HIV/non-AIDS in San Francisco between 2001 and 2015 received care at publicly-funded facilities. These included 723 persons diagnosed in Era 1, 753 persons in Era 2, 658 persons in Era 3, 565 persons in Era 4 and 425 persons in Era 5. Demographic and risk characteristics, stratified by eras, are shown in Table 1. Across all eras, the largest proportion of individuals were males, whites, and men who have sex with men (MSM). In the first three eras (2001–2009), the largest proportion of individuals was between the ages of 30 to 39 years at diagnosis compared to other age groups; however, this shifted to ages 20 to 29 years in Eras 4 and 5.

Overall, there were 729 persons (23%) receiving eiART and 836 persons (27%) receiving bDRT within 3 months of diagnosis. The proportion of individuals by year is presented in Fig 1. Uptake of eiART and bDRT increased significantly from 2001 to 2015 ($p < 0.001$); the proportion was 17% in 2001, decreased over the next 3 years to a nadir of 5% in 2004, then increased steadily to a peak of 74% in 2015. The proportion of individuals receiving bDRT also increased significantly from 2001 to 2015 ($p < 0.001$); the low was 4% in 2001, gradually increased until a peak of 55% in 2012, and declined over the next 3 years to 49% in 2015.

The proportion of cases with eiART and bDRT within 3 months of HIV diagnosis stratified by eras is shown in Fig 2. The proportion of cases with eiART increased overall across eras ($p < 0.001$), ranging from 13% (n = 91) in 2001–2003 to 60% (n = 257) in 2012–2015. The proportion of cases with bDRT also increased overall across eras ($p < 0.001$), rising from a low of 7% in 2001–2003, to a high of 49% in 2010–2012, then decreasing slightly to 46% in Era 2013–2015. Across eras, among the 831 persons who received bDRT within 3 months of diagnosis, 391 individuals (47%) also received eiART within this timeframe. The proportion increased significantly ($p < 0.001$), ranging from 27% in 2001–2003, decreasing to 18% in 2003–2006, rebounding to 29% in Era 2007–2009, rising to 54% in 2010–2012 and plateauing at 76% in 2013–2015.

Demographic and risk characteristics of persons receiving eiART and bDRT within 3 months of diagnosis, stratified by eras, are presented in Table 2. Males were more likely to receive eiART than females and trans females in 2004–2015. Persons <20 and 30–39 years old were more likely to receive eiART than those ages 20–29, 40–49 and ≥ 50 years in 2013–2015. Hispanics/Latinos and Asians/Pacific Islanders were more likely to receive eiART than whites and blacks in 2001–2003. MSM were more likely to receive eiART than persons who inject
drugs (PWID), heterosexuals and persons with other/unknown risks in 2007–2009 and 2013–2015. In 2001–2003, males compared to females and trans females, and MSM compared to PWID, heterosexuals and persons with other/unknown risks, were more likely to receive bDRT. Blacks were less likely to receive bDRT than whites, Hispanics/Latinos and Asians/Pacific Islanders in 2001–2003. No significant differences in demographic and risk characteristics for bDRT in 2004–2015.

Of the 990 persons diagnosed between 2010 and 2015, 237 persons (24%) received eiART and 361 persons (36%) received bDRT within 30 days of diagnosis. The proportion of individuals receiving eiART increased significantly from 13% in 2010–2012 to 38% in 2013–2015 (p < 0.001). The proportion of individuals receiving bDRT rose from 35% in 2010–2012 to 39% in 2013–2015 but the increase was not significant (p = 0.141). Demographic and risk characteristics of persons receiving bDRT are detailed in Table 3. Persons receiving eiART within 30 days of diagnosis were more likely to receive bDRT within 30 days of diagnosis than persons that did not in 2010–2012 (aOR = 2.3, p = 0.001) and 2013–2015 (aOR = 2.8, p < 0.001). There were no significant differences observed in demographic and risk characteristics. Among the 361 persons receiving bDRT, 132 individuals (37%) also received eiART within this timeframe. The proportion increased steadily from 18% in 2010 to 79% in 2015 (p < 0.001).

### Discussion

The proportion of persons newly-diagnosed with HIV/non-AIDS who initiated ART within 3 months of diagnosis increased significantly from 2004 through 2015. The substantial increase
in eART uptake observed in the more recent years likely reflect adoption of revised local and national guidelines, as well as the strategy of treatment as prevention.[2,3,8,9] The decrease seen in 2002 through 2006 may stem from concerns during that time regarding toxicities associated with ART. Disparities observed from 2004 through 2015 were driven primarily by the lower uptake of eART among women, blacks, persons who inject drugs, heterosexuals, and other non-MSM groups. These groups are affected by multiple layers of stigma related to HIV status, race, ethnicity, sexual practices, gender, and substance use. Such compounded stigma is a substantial barrier to health care engagement.[10]

ART has been shown to increase survival and decrease morbidity, and the 2010 San Francisco universal treatment policy was influenced by findings released the previous year demonstrating lower mortality risk among patients initiating ART at higher CD4 counts.[8,9] However, concerns about side effects, the unknown impact of long-term use, and the costs have been found to influence the ART initiation decision for some providers and their patients.[11]

bDRT within 3 months of diagnosis increased steadily from 2004 through 2012, with a slight decline in 2013 to 2015, always remaining less than 40%. bDRT was less common in the early part of the decade, likely because the national guidelines at the time did not include bDRT. The finding that fewer than half of cases had bDRT was unexpected, especially in the more recent years when baseline testing recommendations had been placed for several years and testing had become available to San Francisco residents regardless of insurance coverage. Potential barriers to resistance testing include lack of familiarity with how resistance testing is
ordered, especially in testing centers where HIV is diagnosed but treatment is not routinely provided. Financial barriers to resistance testing would still occur if the person was not a resident of San Francisco or if they migrated out of San Francisco before resistance testing was ordered. Ethnic disparities in treatment access and resistance testing were present in 2001–2003 and lessened in the following eras as treatment and resistance testing scaled up. While eiART involves multiple opportunities for stigma to create disparities, bDRT is a laboratory test that poses little additional risk of stigma or unintended disclosure.

The proportion of individuals receiving both bDRT and eiART within 3 months of diagnosis was highest in 2013–2015, which likely reflects the combined impact of revisions to the treatment and drug resistance testing guidelines. Both eiART and bDRT within 30 days of diagnosis increased between 2010 and 2015. The increase in bDRT was driven primarily by the corresponding increase in eiART. Local and national guideline revisions in recent years recommending treatment initiation upon diagnosis likely propelled the observed increases.

Even for cases receiving bDRT who did not initiate treatment early, baseline genotyping can inform regimen selection upon subsequent ART initiation because the abundance of resistant viruses may decline over time in the absence of selective drug pressure but may be still present in viral archives. Upon ART initiation, even low levels of resistant viruses may increase risk of treatment failure.[12–13] bDRT enables clinical documentation of resistant viruses before they revert and are overgrown by wild-type viruses. In addition, previous studies suggest bDRT may be cost-effective by optimizing regimens and thereby increasing rates of
Table 2. Bivariate analysis of demographic and risk characteristics associated with persons newly-diagnosed with HIV/non-AIDS receiving care at publicly-funded facilities with early initiation of antiretroviral therapy (eiART) and baseline drug resistance testing (bDRT) within 3 months of diagnosis, by treatment guideline eras, San Francisco, 2001–2015 (N = 3,124).

|                      | Total Cases | 2001–2003 Era 1 n = 723 | 2004–2006 Era 2 n = 753 | 2007–2009 Era 3 n = 658 | 2010–2012 Era 4 n = 565 | 2013–2015 Era 5 n = 425 |
|----------------------|-------------|--------------------------|--------------------------|--------------------------|--------------------------|--------------------------|
|                      | %           | p-value                  | %                        | p-value                  | %                        | p-value                  |
| Early Initiation of Antiretroviral Therapy |             |                          |                          |                          |                          |                          |
| Gender               | 0.313       | 0.021                    | 0.042                    | 0.005                    | 0.035                    |                          |
| Male                 | 12.0        | 6.1                      | 18.7                     | 40.4                     | 62.5                     |                          |
| Female/Trans Female | 15.3        | 12.5                     | 10.7                     | 23.8                     | 48.4                     |                          |
| Age (years)          | 0.343       | 0.806                    | 0.307                    | 0.370                    | 0.009                    |                          |
| < 20                 | 15.4        | 9.1                      | 12.5                     | 12.5                     | 87.5                     |                          |
| 20–29                | 10.8        | 7.4                      | 13.2                     | 38.0                     | 58.7                     |                          |
| 30–39                | 14.1        | 6.6                      | 18.4                     | 41.5                     | 70.5                     |                          |
| 40–49                | 13.8        | 5.5                      | 18.8                     | 38.5                     | 54.1                     |                          |
| ≥ 50                 | 5.1         | 9.6                      | 24.1                     | 31.2                     | 47.2                     |                          |
| Race/Ethnicity       | 0.011       | 0.714                    | 0.315                    | 0.147                    | 0.117                    |                          |
| White                | 11.8        | 5.7                      | 20.1                     | 36.0                     | 61.3                     |                          |
| Hispanic/Latino      | 18.2        | 7.7                      | 13.4                     | 41.5                     | 67.2                     |                          |
| Black                | 7.6         | 9.3                      | 15.5                     | 31.1                     | 50.6                     |                          |
| Asian/Pacific Islander | 24.4       | 6.5                      | 21.2                     | 52.3                     | 63.4                     |                          |
| Other/Unknown        | 6.7         | 7.5                      | 12.1                     | 37.9                     | 47.6                     |                          |
| HIV Transmission Risk| 0.218       | 0.120                    | 0.028                    | 0.083                    | 0.046                    |                          |
| Men who have sex with men | 9.7       | 6.3                      | 18.9                     | 39.8                     | 62.6                     |                          |
| Persons who inject drugs/Heterosexual/Other/Unknown | 13.4       | 10.3                     | 10.6                     | 31.0                     | 50.0                     |                          |
| Baseline Drug Resistance Testing |           |                          |                          |                          |                          |                          |
| Gender               | 0.043       | 0.927                    | 0.942                    | 0.656                    | 0.760                    |                          |
| Male                 | 7.7         | 14.2                     | 32.1                     | 48.9                     | 46.6                     |                          |
| Female               | 2.3         | 15.5                     | 31.0                     | 49.1                     | 43.2                     |                          |
| Trans Female         | 0.0         | 16.0                     | 34.2                     | 39.1                     | 38.9                     |                          |
| Age (years)          | 0.376       | 0.604                    | 0.679                    | 0.178                    | 0.320                    |                          |
| < 20                 | 7.7         | 9.1                      | 37.5                     | 75.0                     | 75.0                     |                          |
| 20–29                | 7.0         | 13.5                     | 34.8                     | 50.0                     | 48.0                     |                          |
| 30–39                | 8.1         | 17.0                     | 30.9                     | 48.9                     | 47.3                     |                          |
| 40–49                | 5.0         | 12.0                     | 28.5                     | 41.9                     | 40.0                     |                          |
| ≥ 50                 | 1.7         | 13.7                     | 36.2                     | 55.7                     | 41.5                     |                          |
| Race/Ethnicity       | 8.7         | 0.004                    | 13.3                     | 0.394                    | 30.1                     | 0.536                    | 44.0                     | 0.062                    | 46.5                     | 0.964 |
| Hispanic/Latino      | 8.8         | 18.4                     | 32.9                     | 58.6                     | 43.2                     |                          |
| Black                | 1.0         | 11.0                     | 38.2                     | 44.4                     | 48.0                     |                          |
| Asian/Pacific Islander | 9.8       | 15.2                     | 26.9                     | 50.0                     | 46.3                     |                          |
| Other/Unknown        | 0.0         | 12.5                     | 33.3                     | 44.8                     | 47.6                     |                          |
| HIV Transmission Risk| 0.025       | 0.706                    | 0.699                    | 0.388                    | 0.653                    |                          |
| Men who have sex with men | 8.1       | 14.3                     | 32.0                     | 48.9                     | 46.5                     |                          |
| Persons who inject drugs | 1.9       | 13.7                     | 30.2                     | 49.0                     | 41.9                     |                          |
| Heterosexual         | 0.0         | 20.0                     | 38.3                     | 52.3                     | 50.0                     |                          |
| Other/Unknown        | 0.0         | 7.4                      | 23.1                     | 30.0                     | 30.8                     |                          |

https://doi.org/10.1371/journal.pone.0213167.t002
durable suppression, particularly in settings which have increasing prevalence of transmitted drug resistance, such as San Francisco.[14–16]

Associations observed among the study sample may differ from individuals receiving care at private facilities. Nonetheless, since publicly-funded facilities provide care for three-quarters of newly-diagnosed cases annually, these results are representative of a majority of the recently-diagnosed HIV population in San Francisco.[17] Data for cases with bDRT conducted at other laboratories would not be reflected in this analysis. However, since the ARI UCSF LCV conducts most of the DRT for publicly-funded facilities in San Francisco, data for the vast majority of this study population were available.

Both eiART and bDRT were adopted by local clinical practices in San Francisco as early as 2004, before the U.S. treatment guidelines included these recommendations on a national basis. Further analyses are needed to evaluate the benefits of the combined practice of eiART and bDRT in ultimately improving clinical outcomes.

**Author Contributions**

**Conceptualization:** Hong-Ha M. Truong.

**Data curation:** Hong-Ha M. Truong.

**Formal analysis:** Hong-Ha M. Truong, Sharon Pipkin.

**Funding acquisition:** Hong-Ha M. Truong.
Writing – original draft: Hong-Ha M. Truong.
Writing – review & editing: Sharon Pipkin, Robert M. Grant, Teri Liegler, Kara J. O’Keefe, Susan Scheer.

References

1. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/guidelines.

2. INSIGHT START Study Group, Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015; 373:795–807. https://doi.org/10.1056/NEJMoa1506816 PMID: 26192873

3. TEMPRANO ANRS 12136 Study Group, Daniel C, Moh R, Gabillard D, Badjie A, Le Carrou J, et al. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med. 2015; 373:808–22. https://doi.org/10.1056/NEJMoa1507198 PMID: 26193126

4. The New York Times. City Endorses New Policy for Treatment of H.I.V. http://www.nytimes.com/2010/04/04/us/04sf-treatment.html.

5. Wegner SA, Wallace MR, Aronson NE, Tasker SA, Blazes DL, Tamminga C, et al. Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: results of the clinical efficacy of resistance testing trial. Clin Infect Dis. 2004; 38:723–730. https://doi.org/10.1086/381266 PMID: 14986258

6. Pao D, Andrady U, Clarke J, Dean G, Drake S, Fisher M, et al. Long-term persistence of primary genotypic resistance after HIV-1 seroconversion. J Acquir Immune Defic Syndr. 2004; 3:1570–1573.

7. Barbour JD, Hecht FM, Wrin T, Liegler TJ, Ramstead CA, Busch MP, et al. Persistence of primary drug resistance among recently HIV-1 infected adults. AIDS. 2004; 18:1683–1689. PMID: 15280779

8. Kitahata MM, Gange SJ, Abraham AG, Merriman B, Saag MS, Justice AC, et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med. 2009; 360(18):1815–1826. https://doi.org/10.1056/NEJMoa0807252 PMID: 19339714

9. When To Start Consortium, Sterne JA, May M, Costagliola D, de Wolf F, Phillips AN, et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-infected patients: a collaborative analysis of 18 HIV cohort studies. Lancet. 2009; 373(9672):1352–1363. https://doi.org/10.1016/S0140-6736(09)60612-7 PMID: 19361855

10. Adimora AA, Schoenbach VJ. Social context, sexual networks, and racial disparities in rates of sexually transmitted infections. J Infect Dis. 2005; 191 Suppl 1:S115–122.

11. Crum NF, Riffenburgh RH, Wegner S, Tasker SA, Spooner KM, Armstrong AW, et al. Comparisons of causes of death and mortality rates among HIV-infected persons: analysis of the pre-, early, and late HAART (highly active antiretroviral therapy) eras. J Acquir Immune Defic Syndr. 2006; 41(2):194–200. PMID: 16394852

12. Johnson JA, Li JF, Wei X, Lipscomb J, Irbeck D, Craig C, et al. Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naïve populations and associate with reduced treatment efficacy. PLoS Med. 2008; 5:e158. https://doi.org/10.1371/journal.pmed.0050158 PMID: 18666824

13. Paredes R, Lalamra CM, Ribaudo HJ, Schackman BR, Shikuma C, Giguel F, et al. Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failures. J Infect Dis. 2010; 201:662–671. https://doi.org/10.1086/650543 PMID: 20102271

14. Weinstein MC, Goldie SJ, Losina E, Cohen CJ, Baxter JD, Zhang H, et al. Use of genotypic resistance testing to guide HIV therapy: clinical impact and cost-effectiveness. Ann Intern Med. 2001; 134:440–450. PMID: 11255519

15. Sax PE, Islam R, Walensky RP, Losina E, Weinstein MC, Goldie SJ, et al. Should resistance testing be performed for treatment-naive HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis. 2005; 41:1316–1323. https://doi.org/10.1086/496984 PMID: 16206108

16. Truong HM, Kellogg T, McFarland W, Louie B, Klausner JK, Philip SS, et al. Sentinel surveillance of HIV-1 transmitted drug resistance, acute infection and recent infection. PLoS One. 2011; 6:e25281. https://doi.org/10.1371/journal.pone.0025281 PMID: 22046237

17. Truong HM, Pipkin S, O’Keefe KJ, Louie B, Liegler T, McFarland W, et al. Recent infection, sexually transmitted infections and transmission clusters frequently observed among persons newly-diagnosed with HIV in San Francisco. J Acquir Immune Defic Syndr. 2015; 69:606–609. https://doi.org/10.1097/QAI.0000000000000681 PMID: 25967271